Analysts/Institutional Investor Meet/Con. Call Updates

12 August 2026 To To The Listing Department, The Corporate Relations Department, National Stock Exchange of India Limited BSE Limited NSE Symbol: SAILIFE BSE Scrip code: 544306 Dear Sir/Madam, Sub: Transcript of the Earnings conference call organized on 07 August 2026 Referring to our letter dated 30 July 2026, we are enclosing herewith the Transcript of the Earnings Conference Call organized on August 07, 2026, post declaration of the Un-audited Financial Results of the Company for the quarter ended 30 June 2026. Please take the information on your record. Thanking you. Yours faithfully, For Sai Life Sciences Limited Runa Karan Company Secretary & Compliance Officer Membership No.: A13721 Encl.: as above Sai Life Sciences Limited (CIN: L24110TG1999PLC030970) Corporate office Registered office Contact us T: +91 40 6815 6000, # L4-01 & 02, SLN Terminus, Survey Plot No. DS-7, IKP Knowledge Park, Turkapally F: +91 40 6815 6199 #133, Gachibowli Miyapur Road, (V), Shameerpet Mandal, Medchal-Malkajgiri E: info@sailife.com Gachibowli, Hyderabad – 500032, (Dist), Hyderabad -500078, Telangana, India. W: www.sailife.com Telangana, India. Sai Life Sciences Limited Q1 FY27 Earnings Conference Call August 07, 2026 MANAGEMENT: MR. KRISHNA KANUMURI – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER – SAI LIFE SCIENCES LIMITED MR. SIVA CHITTOR – WHOLE-TIME DIRECTOR AND CHIEF FINANCIAL OFFICER – SAI LIFE SCIENCES LIMITED MODERATOR: MR. DIWAKAR PINGLE – E&Y INVESTOR RELATIONS Sai Life Sciences Limited August 07, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Sai Life Sciences Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star and then zero on your touch- tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Diwakar Pingle from E&Y Investor Relations. Thank you, and over to you, sir. Diwakar Pingle: Thank you so much, Sagar. Good evening to all the participants on this call. Warmly welcome you to the Q1 FY27 earnings call of Sai Life Sciences Limited. Before we proceed, on the call, let me remind you that the discussion may contain forward-looking statements that may involve known, unknown risks, uncertainties and other factors. It must be viewed in conjunction with our business risks that could cause future result performance or achievement to differ significantly from what is expressed or implied by such forward-looking statements. Please note that we mail the results and the same are available on our website too. In case you have not received the same, you can write to my team at E&Y and we'll be happy to send the same over to you. To take us through the results and answer your questions today, we have the top management of Sai Life Sciences Limited, represented by Mr. Krishna Kanumuri, Managing Director and Chief Executive Officer; and Mr. Siva Chittor, Whole-Time Director and Chief Financial Officer. We will start the call with a brief overview of the quarter gone past and then conduct the Q&A session. With that said, I'll now hand over the call to Krishna Kanumuri. Over to you, Krishna. Krishna Kanumuri: Thank you, Diwakar. Good evening, everyone, and thank you for joining us for our Q1 FY27 earnings call. We are pleased with the progress we have made in the first quarter and importantly with the momentum we are seeing across our business. Revenue for the quarter grew by 12% year-over-year, supported by growth across two businesses, particularly in the CRO, which grew by 26% year-over- year. The Q1 performance has been in line with our expectations and we remain confident of our growth trajectory and prospects. As we have discussed in the previous earnings call, we expect a stronger H2 with planned capacity expansion going live in the second half of the year. As we look ahead, we believe Sai is at an important point in evolution from being a strong small molecule CRDMO to becoming a technology-led, multi-modality partner with capabilities spanning discovery through commercial manufacturing. Let me begin with the broader environment. From a customers’ standpoint, geopolitical uncertainty and concerns around intellectual property have made India an increasingly important part of their diversification strategies. I would say this trend has not only continued but strengthened. In the biotech environment, we have seen several large acquisitions and about 18 IPOs in the US. Page 2 of 16 Sai Life Sciences Limited August 07, 2026 As investors cash out, we expect capital to flow back into funding new biotech companies. The clear message we are picking up is that these new companies will be built with even leaner in-house capabilities, which should continue to support healthy demand for our sector. Our pipeline is being built for the long haul. Through dedicated FTE models, we are building deep, durable relationships with our customers' development team. This is impacting our pipeline in three distinct ways. Molecules from biotech companies that we have supported being acquired by pharmaceutical collaborators, molecules from acquired companies transferred to us, and finally, molecules from our own FTE relationships progressing into late-stage development. Together, these three create a broad and sustainable funnel for the business. As we engage with our customers, it is clear that the complexity and range of technologies they are pursuing are broader than ever. This aligns very well with our strategy of building strong R&D capabilities across diverse range of modalities. We believe the biggest long-term opportunity is to continue building a fully integrated delivery engine, from discovery through commercial manufacturing. We are seeing a clear traction with our clients beginning to engage with us across the full spectrum of our services. We are well positioned to transition from integrated small molecule CRDMO to a full-fledged multi-modality integrated CRDMO. We have already made meaningful progress and will continue to accelerate this build-out. Peptides are an important modality for us. We have one of the largest and fastest-growing peptide team within discovery. While GLP-1s received significant attention, there is substantial work underway in macrocyclic peptides, peptide-drug conjugates, and radiochemistry applications. Our first dedicated peptide development lab is coming online shortly for a top-tier pharma company. We are also expanding the scope of our peptides center of excellence support to both discovery and development teams with ability to deliver pilot quantities for clinical trials. In addition, we plan to break ground for a peptide manufacturing facility at our new greenfield site near Hyderabad, which is expected to be operational in 2028. We are close to opening our XDC Center of Excellence, which will support both discovery and development teams in the synthesis of payloads, linkers, and conjugation across antibodies, peptides, PROTACs, and oligonucleotides There is an increasing need to support our development programs with greater speed and flexibility. We are working on building new capacity specifically designed for early to mid-stage deliveries and will be an important part of the expansion at our new greenfield manufacturing site. Formulation is another area we are entering. While we are still about six months away from being operationally ready, we are seeing significant interest from our pharma partners. There is a clear demand for integrated offering that can deliver both custom first-in-human APIs and drug products with speed, helping customers accelerate development timelines. Scientific excellence remains at the heart of this evolution. Page 3 of 16 Sai Life Sciences Limited August 07, 2026 Over the past few years, we have de [Showing first 8,000 characters — download PDF for full document]